Navigation Links
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
Date:4/3/2013

posed acquisition by Valeant of Obagi, the expected timing of the transaction and satisfaction of closing conditions.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during the pendency of the acquisition; the risk that the operations of the two companies will not be integrated successfully; and other risks and uncertainties, including those detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission ("SEC") and in the case of Valeant, the Canadian Securities Administrators ("CSA"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "RISK FACTORS" in their annual reports on Form 10-K for the year ended December 31, 2012, which have been filed with the SEC and in the case of Valeant, the CSA. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the companies' actual results to differ materially from expected and historical results. The companies assume no obligation to publicly update any forward-looking statements, whether as a result of new information
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Private Exchange Offer
2. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
3. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
4. Valeant Completes Acquisition Of Natur Produkt In Russia
5. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
6. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
7. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
8. Valeant Pharmaceuticals Announces New Management Appointments
9. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
10. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
11. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 RadiologyAuction will have their first auction ... product demonstrations at the end of the auction on ... Kodak and Fuji Cr,s, Agfa and Sony, printers and ... event. Various imaging equipment will be available at later ... After years of buying and selling imaging equipment, the ...
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... announces that a new market research report ... Byetta (Type 2 Diabetes) – Analysis ... http://www.reportlinker.com/p0657148/Byetta-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Byetta (Type ... 2020 Summary ...
... Reportlinker.com announces that a new market research ... Aesthetic Lasers and Energy Devices - ... http://www.reportlinker.com/p0575304/Aesthetic-Lasers-and-Energy-Devices---Global-Market-Briefing-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Beauty_Salon_and_Services Aesthetic Lasers ... 2017 Summary ...
Cached Medicine Technology:Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 5Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 2Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 3Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 4Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 5Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 7Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 8Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 9
(Date:5/4/2015)... 2015 “ LiveSchool ” was featured ... takes a look at the latest and coolest applications ... Toohey, the host of AppWatch and technology expert, conducted ... application allows teachers to reward students with good behavior. ... especially in the classroom. And the good people ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is set to host its annual Ace ... Orange, NJ on June 1, 2015. Since 2010, the ... through LRF. , This year, the Lymphoma Research Foundation ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
(Date:5/4/2015)... May 04, 2015 The opportunity for children ... life are the motivating forces behind The Fairy Godmother Next ... and author Amy L. Stark. , The inspiration for the ... next door comes from Stark’s desire to be a fairy ... a fairy godmother to my neighbors’ children since they were ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... Ustekinumab injections every 3 months a more convenient ... News) -- The drug ustekinumab has been shown to ... moderate-to-severe psoriasis in two studies published in this week,s ... by binding to two interleukins, proteins produced by the ...
... leadership in proposing prescription,drug marketing reform and transparency, ... believes,New York has a paramount interest in passing ... undue influence that,pharmaceutical companies have over prescribing decisions ... treatment they receive., The reforms include banning ...
... worldwide cancer incidence, researchers at the Moores Cancer Center ... Department of Family and Preventive Medicine have shown a ... ultraviolet B (UVB), and breast cancer. , UVB ... This form of vitamin D also is available through ...
... May 15 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... March 31, 2008. Pharmasset reported a net loss ... per share for the,quarter ended March 31, 2008, ...
... The following is a,statement from Larry Minnix, President ... Aging:, "Today,s GAO report points out yet again ... of nursing homes in this country. If,we want to ... need to,rethink our approach from the bottom up., ...
... Theranostics Health (THX) today,announced that it ... agreement with Duke University. This relationship will,provide ... technologies: Laser,Capture Microdissection (LCM) and Reverse Phase ... technologies provides a powerful,mechanism to accurately and ...
Cached Medicine News:Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8Health News:Theranostics Health Signs Research Collaboration Agreement 2
Plus cylinders only trial lens set....
Trial Lens Sets....
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Medicine Products: